Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Januar 2019

Planlagt Fastgjort Låst Flyttet Genmab
2.8k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Plimsoller
    wrote on sidst redigeret af
    #484

    Regner man med SC på markedet allerede i H2-2019?

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #485

      Så skal det flaske sig med data til sommer og en hurtig PR.

      1 Reply Last reply
      0
      • P Offline
        P Offline
        Plimsoller
        wrote on sidst redigeret af
        #486

        Ok. Lyder lidt hurtigt, men det vil da
        være fremragende for salget i 2020.

        1 Reply Last reply
        0
        • Legolas23L Offline
          Legolas23L Offline
          Legolas23
          wrote on sidst redigeret af
          #487

          Kan man ikke anvende RTOR på SQ ?

          1 Reply Last reply
          0
          • P Offline
            P Offline
            Plimsoller
            wrote on sidst redigeret af
            #488

            @Legolas
            Det blev diskuteret her på chatten for et godt stykke tid, og det var der delte meninger om.

            1 Reply Last reply
            0
            • T Offline
              T Offline
              Tandfeen-2
              wrote on sidst redigeret af
              #489

              Så begriber jeg ikke deres kursmål på 1050

              1 Reply Last reply
              0
              • Legolas23L Offline
                Legolas23L Offline
                Legolas23
                wrote on sidst redigeret af
                #490

                Jeg fulgte de godt, og jeg spørger igen, fordi jeg lige så @Bulder online. Man må antage med en rigtig god dialog med FDA at RTOR ikke lå særlig langt væk. Vi få nok ikke et klart svar, men vi må gisne her på siden og i baglandet.

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  Plimsoller
                  wrote on sidst redigeret af
                  #491

                  Ok. Ja jeg ved det bestemt ikke. Kan blot håbe.

                  1 Reply Last reply
                  0
                  • StockBullS Offline
                    StockBullS Offline
                    StockBull
                    wrote on sidst redigeret af
                    #492

                    Ved ikke om SC kommer på marked i 2019 men bare det der kommer positiv data kan vel få kursen til at rykke for så er 2020 og 4.5 mia i dara
                    salg 99% sikker

                    1 Reply Last reply
                    0
                    • StockBullS Offline
                      StockBullS Offline
                      StockBull
                      wrote on sidst redigeret af
                      #493

                      samt vejen op til 10 mia usd er lagt, så er det bare op til sælgerne

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gentogen
                        wrote on sidst redigeret af
                        #494

                        OM RTOR hedder det, at "Supplements with CMC formulation changes and supplements with pharmacology/toxicology data will be excluded." jeg er langt fra ekspert i terminologien , men gætter vel lidt på, at det omfatter SQ

                        1 Reply Last reply
                        0
                        • StockBullS Offline
                          StockBullS Offline
                          StockBull
                          wrote on sidst redigeret af
                          #495

                          vis kursmål ? Tandfeen, JPM er på 1150 og de opjustere vel når RTOR og SC er igennem nåleøjet

                          1 Reply Last reply
                          0
                          • StockBullS Offline
                            StockBullS Offline
                            StockBull
                            wrote on sidst redigeret af
                            #496

                            JPM forventer MAIA begunder at sælge i August 2019 og ser RTOR som en joker der kan give target et hak opad

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #497

                              Joker? - Snarere spar 5, der som bekendt rydder bordet 😉

                              1 Reply Last reply
                              0
                              • StockBullS Offline
                                StockBullS Offline
                                StockBull
                                wrote on sidst redigeret af
                                #498

                                2019 guidance could have a degree of conservatism given
                                recent results
                                The key guidance metric the market is focused on is Darzalex in-market sales. There
                                is a focus on earnings and operating profit by some investors; however, given that
                                Genmab are building a pipeline for future value creation we do not believe investors
                                should be too focused on 2019 operating profit. Heading into 2019 we expect
                                Genmab to guide for Darzalex in market sales of $2.8-3.1bn, factoring in the launch of MAIA although

                                1 Reply Last reply
                                0
                                • StockBullS Offline
                                  StockBullS Offline
                                  StockBull
                                  wrote on sidst redigeret af
                                  #499

                                  also including the possibility of any potential price adjustment exUS. We forecast Darzalex sales of $3.1bn which is broadly in line with consensus of
                                  $3.09bn. We expect guidance for revenue of DKr3,400-3,800m and Operating profit
                                  of DKr1,600-1,800m. Our estimates are towards the top end of this range, with
                                  consensus slightly above the top end of the range. Consensus appears to factor in
                                  c.$50m more milestones in FY19; however ,with Darzalex forecasts in line we do not
                                  expect significant downsid

                                  1 Reply Last reply
                                  0
                                  • StockBullS Offline
                                    StockBullS Offline
                                    StockBull
                                    wrote on sidst redigeret af
                                    #500

                                    with the FY19 guidance in Feb'19.

                                    1 Reply Last reply
                                    0
                                    • StockBullS Offline
                                      StockBullS Offline
                                      StockBull
                                      wrote on sidst redigeret af
                                      #501

                                      Consensus Comparison
                                      Our 2018 revenue estimates are in line with Bloomberg consensus in 2018, although
                                      we are ahead on Core Operating profit (5% ahead) as consensus is forecasting OpEx
                                      towards the top end of the range vs. our assumption for the mid-point. We are
                                      significantly ahead on EPS as we believe consensus misses the recognition of
                                      deferred tax assets, which will wipe out the Q1-Q3 tax charge. In 2019 we are below
                                      consensus (6%/DKr220m on the top line and 14%/DKr292m on Op Profit) as
                                      conse

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #502

                                        @gentogen: "formulation changes" er vel netop når de tilsætter rhuph20?

                                        1 Reply Last reply
                                        0
                                        • StockBullS Offline
                                          StockBullS Offline
                                          StockBull
                                          wrote on sidst redigeret af
                                          #503

                                          as
                                          consensus appears to factor in additional $50m in milestones vs. our estimates. In
                                          2020, we are broadly in line with consensus on the topline and operating profit, and
                                          below on net income – we assume consensus still has tax losses being utilised when
                                          we believe they will be fully utilised by 2020

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger